Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 45, 2016, Pages E6946-E6954

  Pierce, Brian G ^a   Keck, Zhen Yong ^b   Lau, Patrick ^b   Fauvelle, Catherine ^c,d   Gowthaman, Ragul ^a   Baumert, Thomas F ^c,d,e   Fuerst, Thomas R ^a   Mariuzza, Roy A ^a   Foung, Steven K H ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hopitaux Universitaires de Strasbourg   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Alanine scanning; Clustering; HCV; Hotspots; Immune recognition

Indexed keywords

ALANINE; CD81 ANTIGEN; GLYCOPROTEIN E2; HEPATITIS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRAL PROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY MAPPING; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; EPITOPE MAPPING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

EID: 84994508072     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614942113     Document Type: Article

References (57)

1. Rosen HR (2011) Clinical practice. Chronic hepatitis C infection. N Engl J Med 364(25):2429-2438.
2. Cox AL (2015) MEDICINE. Global control of hepatitis C virus. Science 349(6250):790-791.
3. Walker CM, Grakoui A (2015) Hepatitis C virus: Why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 35:137-143.
4. Lontok E, et al. (2015) Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62(5):1623-1632.
5. Veldt BJ, et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147(10):677-684.
6. Scarselli E, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21(19):5017-5025.
7. Pileri P, et al. (1998) Binding of hepatitis C virus to CD81. Science 282(5390):938-941.
8. Douam F, et al. (2014) Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology 59(3):776-788.
9. Kong L, Jackson KN, Wilson IA, Law M (2015) Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 11:148-157.
10. Drummer HE (2014) Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol 5:329.
11. Giang E, et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 109(16):6205-6210.
12. Keck Z, et al. (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 87(1):37-51.
13. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14(1):25-27.
14. Broering TJ, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83(23):12473-12482.
15. Sabo MC, et al. (2011) Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 85(14):7005-7019.
16. Alhammad Y, et al. (2015) Monoclonal antibodies directed toward the hepatitis C virus glycoprotein E2 detect antigenic differences modulated by the N-terminal hypervariable region 1(HVR1), HVR2, and intergenotypic variable region. J Virol 89(24):12245-12261.
17. Ball JK, Tarr AW, McKeating JA (2014) The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 105:100-111.
18. Kong L, et al. (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342(6162):1090-1094.
19. Khan AG, et al. (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509(7500):381-384.
20. Khan AG, Miller MT, Marcotrigiano J (2015) HCV glycoprotein structures: what to expect from the unexpected. Curr Opin Virol 12:53-58.
21. Deng L, et al. (2014) Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization. Proc Natl Acad Sci USA 111(29):10690-10695.
22. Li Y, et al. (2015) Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem 290(16):10117-10125.
23. Bailey JR, et al. (2015) Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest 125(1):437-447.
24. Keck ZY, et al. (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78(17):9224-9232.
25. Keck ZY, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8(4):e1002653.
26. Hadlock KG, et al. (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74(22):10407-10416.
27. Keck ZY, et al. (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82(12):6061-6066.
28. Marks DS, Hopf TA, Sander C (2012) Protein structure prediction from sequence variation. Nat Biotechnol 30(11):1072-1080.
29. Kamisetty H, Ovchinnikov S, Baker D (2013) Assessing the utility of coevolution-based residue-residue contact predictions in a sequence- and structure-rich era. Proc Natl Acad Sci USA 110(39):15674-15679.
30. Kong L, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci USA 109(24):9499-9504.
31. Potter JA, et al. (2012) Toward a hepatitis C virus vaccine: The structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol 86(23):12923-12932.
32. Pantua H, et al. (2013) Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol 425(11):1899-1914.
33. Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H (2014) UpSet: Visualization of intersecting sets. IEEE Trans Vis Comput Graph 20(12):1983-1992.
34. Goffard A, et al. (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79(13):8400-8409.
35. Kortemme T, Kim DE, Baker D (2004) Computational alanine scanning of proteinprotein interfaces. Sci STKE 2004(219): pl2.
36. Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21(3):379-384.
37. Keck ZY, et al. (2009) Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 83(12):6149-6160.
38. Morin TJ, et al. (2012) Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 8(8):e1002895.
39. Keck ZY, et al. (2011) Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol 85(20):10451-10463.
40. Fofana I, et al. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143(1):223-233 e229.
41. Keck ZY, et al. (2014) Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog 10(8):e1004297.
42. Keck ZY, et al. (2016) Antibody response to hypervariable region 1 interferes with broadly neutralizing antibodies to hepatitis C virus. J Virol 90(6):3112-3122.
43. Babcock GJ, et al. (2014) High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One 9(6):e100325.
44. Owsianka AM, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80(17):8695-8704.
45. Rothwangl KB, Manicassamy B, Uprichard SL, Rong L (2008) Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: Putative CD81 binding region 1 is not involved in CD81 binding. Virol J 5:46.
46. Lavie M, et al. (2014) Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol 88(18):10584-10597.
47. Wang Y, et al. (2011) Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem 286(51):44218-44233.
48. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592-598.
49. Dey B, et al. (2009) Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 5(5):e1000445.
50. Porta C, et al. (2013) Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 9(3):e1003255.
51. Cowton VM, et al. (2016) Role of conserved E2 residue W420 in receptor binding and hepatitis C virus infection. J Virol 90(16):7456-7468.
52. Fofana I, et al. (2013) A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits hepatitis C virus cell-cell transmission. PLoS One 8(5):e64221.
53. Suzuki R, Shimodaira H (2006) Pvclust: An R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22(12):1540-1542.
54. Hubbard SJ, Thornton JM (1993) NACCESS (Department of Biochemistry and Molecular Biology, University College London, London), 2.1.1.
55. Dimitrova M, et al. (2008) Sustained delivery of siRNAs targeting viral infection by celldegradablemultilayered polyelectrolyte films. Proc Natl Acad Sci USA 105(42):16320-16325.
56. Keck ZY, et al. (2005) Analysis of a highly flexible conformational immunogenic domain A in hepatitis C virus E2. J Virol 79(21):13199-13208.
57. Owsianka AM, et al. (2008) Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89(Pt 3):653-659.